Vor Biopharma(NASDAQ) VOR

Vor Biopharma Inc. treats autoimmune diseases and blood cancer. These therapies fight sickness while protecting healthy cells. The company focuses on patients needing advanced treatment options.

Fighting Sickness at the Source

• Autoimmune Therapies: Developing telitacicept for generalized myasthenia gravis, a muscle weakness disorder, and Sjögren’s disease, an immune system condition.
• Hematopoietic Stem Cells: Engineering blood-forming cells that lack specific proteins to protect them from targeted cancer treatments.
• Oncology Programs: Testing candidates such as Trem-cel and VCAR33 to treat acute myeloid leukemia, a type of blood cancer.

New Licenses and Trials

• In-licensed telitacicept from RemeGen Co., Ltd. in June 2025 for development and commercialization outside Greater China.
• Enrolled the first patient in the United States for a global Phase 3 clinical trial in July 2024.
• Dosed the first patient in a Phase 3 clinical trial for Sjögren’s disease in March 2026.
• Raised $74.9 million through a private placement of common stock in March 2026.

Science That Protects Healthy Cells

Vor Biopharma uses an engineered stem cell platform to remove specific proteins from healthy blood cells. This technology helps protect a patient’s healthy immune system during powerful cancer treatments.

The Numbers Behind the Research

• Cash, cash equivalents, and marketable securities totaled $466.1 million as of June 30, 2026.
• Market capitalization was $999.7 million in Q2 2026, up 392.6% year over year.
• Net loss was $282.4 million for the six-month period ended June 30, 2026, compared to $1.6 billion in the prior year period.
• The company expects its existing cash resources to fund operating expenses into early 2029.

Bottom Line

Vor Biopharma is expanding its clinical reach by combining internal stem cell research with licensed autoimmune therapies. Success depends on upcoming Phase 3 trial data and continued access to capital markets.